Skip to main content
. Author manuscript; available in PMC: 2024 Jan 5.
Published in final edited form as: Clin Cancer Res. 2023 Jul 5;29(13):2394–2400. doi: 10.1158/1078-0432.CCR-23-0036

Figure 1. Synergism of devimistat with chemotherapy and effect on mitochondrial respiration in biliary cancer cell lines.

Figure 1.

(A) Viability of the biliary cancer cell lines (TFK-1, RCB1292 and RCB1293) in response to different concentrations of gemcitabine and cisplatin (GC) alone, devimistat alone (dose less than IC50 for each cell line; 100μM for TFK-1 and RCB1292, 150μM for RCB1293), or the combination. Data presented as mean ± SD (n=4). Data were fitted into a four-parameter dose-response curve. Synergy scores for GC + devimistat showed synergism for RCB1292 (11.24; p<0.001) and RCB1293 (10.85; p<0.001), and additive effect for TFK-1 (5.47; p<0.001) per HSA model by SynergyFinderPlus; (B) Oxygen consumption rate (OCR) with devimistat via Agilent Seahorse assay using four arms: 50μM once, 100μM once, 12.5μM every 18 minutes x 4 doses, and 25μM every 18 minutes x 4 doses. No difference between divided dosing versus one-time dosing at 90-minutes. Data presented as mean ± SEM (n=5); (C) OCR with devimistat via Resipher assay using 4 arms in (B) along with control (DMSO) (n=5). (D) Quantitation of OCR change via Resipher assay at 24 hours and 48 hours (mean ± SD; n=5) using non-paired two-tail t-test. ns, not significant, **: p<0.01, ***: p<0.001.